Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916967884> ?p ?o ?g. }
- W2916967884 endingPage "168" @default.
- W2916967884 startingPage "151" @default.
- W2916967884 abstract "ERK1 and ERK2 are key protein kinases that contribute to the Ras-Raf-MEK-ERK MAP kinase signalling module. This pathway participates in the control of numerous processes including apoptosis, cell proliferation, the immune response, nervous system function, and RNA synthesis and processing. MEK1/2 activate human ERK1/2 by first catalyzing the phosphorylation of Y204/187 and then T202/185, both residues of which occur within the activation segment. The phosphorylation of both residues is required for enzyme activation. The only Raf substrates are MEK1/2 and the only MEK1/2 substrates are ERK1/2. In contrast, ERK1/2 catalyze the phosphorylation of many cytoplasmic and nuclear substrates including transcription factors and regulatory molecules. The linear MAP kinase pathway branches extensively at the ERK1/2 node. ERK1/2 are proline-directed kinases that preferentially catalyze the phosphorylation of substrates containing a PxS/TP sequence. The dephosphorylation and inactivation of ERK1/2 is catalyzed by dual specificity phosphatases, protein-tyrosine specific phosphatases, and protein-serine/threonine phosphatases. The combined functions of kinases and phosphatases make the overall process reversible. To provide an idea of the complexities involved in these reactions, somatic cell cycle progression involves the strict timing of more than 32,000 phosphorylation and dephosphorylation events as determined by mass spectrometry. The MAP kinase cascade is perhaps the most important oncogenic driver of human cancers and the blockade of this signalling module by targeted inhibitors is an important anti-tumor strategy. Although numerous cancers are driven by MAP kinase pathway activation, thus far the only orally effective approved drugs that target this signaling module are used for the treatment of BRAF-mutant melanomas. The best treatments include the combination of B-Raf and MEK inhibitors (dabrafenib and trametinib, encorafenib and binimetinib, vemurafenib and cobimetanib). However, resistance to these antagonists occurs within one year and additional treatment options are necessary. Owing to the large variety of malignancies that are driven by dysregulation of the MAP kinase pathway, additional tumor types should be amenable to MAP kinase pathway inhibitor therapy. In addition to new B-Raf and MEK inhibitors, the addition of ERK inhibitors should prove helpful. Ulixertinib, MK-8353, and GDC-0994 are orally effective, potent, and specific inhibitors of ERK1/2 that are in early clinical trials for the treatment of various advanced/metastatic solid tumors. These agents are effective against cell lines that are resistant to B-Raf and MEK1/2 inhibitor therapy. Although MK-8353 does not directly inhibit MEK1/2, it decreases the phosphorylation of ERK1/2 as well as the phosphorylation of RSK, an ERK1/2 substrate. The decrease in RSK phosphorylation appears to be a result of ERK inhibition and the decrease in ERK1/2 phosphorylation is related to the inability of MEK to catalyze the phosphorylation of the ERK–MK-8353 complex; these decreases characterize the ERK dual mechanism inhibition paradigm. Additional work will be required to determine whether ERK inhibitors will be successful in the clinic and are able to forestall the development of drug resistance of the MAP kinase pathway." @default.
- W2916967884 created "2019-03-02" @default.
- W2916967884 creator A5050801402 @default.
- W2916967884 date "2019-04-01" @default.
- W2916967884 modified "2023-10-16" @default.
- W2916967884 title "Targeting ERK1/2 protein-serine/threonine kinases in human cancers" @default.
- W2916967884 cites W1490238718 @default.
- W2916967884 cites W1498495634 @default.
- W2916967884 cites W1501199419 @default.
- W2916967884 cites W1573821584 @default.
- W2916967884 cites W1656231611 @default.
- W2916967884 cites W1691796058 @default.
- W2916967884 cites W1718256562 @default.
- W2916967884 cites W1771087982 @default.
- W2916967884 cites W1808530289 @default.
- W2916967884 cites W1881469793 @default.
- W2916967884 cites W1891334654 @default.
- W2916967884 cites W1899552864 @default.
- W2916967884 cites W1950829641 @default.
- W2916967884 cites W1966285532 @default.
- W2916967884 cites W1968427979 @default.
- W2916967884 cites W1969035452 @default.
- W2916967884 cites W1970174659 @default.
- W2916967884 cites W1970527559 @default.
- W2916967884 cites W1973642840 @default.
- W2916967884 cites W1975436091 @default.
- W2916967884 cites W1976096319 @default.
- W2916967884 cites W1978572651 @default.
- W2916967884 cites W1985865045 @default.
- W2916967884 cites W1986753065 @default.
- W2916967884 cites W1987920150 @default.
- W2916967884 cites W1989221709 @default.
- W2916967884 cites W1989411375 @default.
- W2916967884 cites W1991401350 @default.
- W2916967884 cites W1994954884 @default.
- W2916967884 cites W1995858338 @default.
- W2916967884 cites W1998404049 @default.
- W2916967884 cites W1998809668 @default.
- W2916967884 cites W2000390423 @default.
- W2916967884 cites W2008525757 @default.
- W2916967884 cites W2011762975 @default.
- W2916967884 cites W2014446189 @default.
- W2916967884 cites W2020293198 @default.
- W2916967884 cites W2020442337 @default.
- W2916967884 cites W2022920832 @default.
- W2916967884 cites W2029968439 @default.
- W2916967884 cites W2030205108 @default.
- W2916967884 cites W2033630329 @default.
- W2916967884 cites W2034048944 @default.
- W2916967884 cites W2034975420 @default.
- W2916967884 cites W2042629507 @default.
- W2916967884 cites W2043617798 @default.
- W2916967884 cites W2048411595 @default.
- W2916967884 cites W2049885874 @default.
- W2916967884 cites W2050573392 @default.
- W2916967884 cites W2052016211 @default.
- W2916967884 cites W2052420692 @default.
- W2916967884 cites W2053286013 @default.
- W2916967884 cites W2054466658 @default.
- W2916967884 cites W2055380229 @default.
- W2916967884 cites W2056184329 @default.
- W2916967884 cites W2056415191 @default.
- W2916967884 cites W2058839898 @default.
- W2916967884 cites W2060070314 @default.
- W2916967884 cites W2062289724 @default.
- W2916967884 cites W2062458432 @default.
- W2916967884 cites W2067405360 @default.
- W2916967884 cites W2070727232 @default.
- W2916967884 cites W2071900417 @default.
- W2916967884 cites W2076674954 @default.
- W2916967884 cites W2079384315 @default.
- W2916967884 cites W2083695927 @default.
- W2916967884 cites W2091455173 @default.
- W2916967884 cites W2093691792 @default.
- W2916967884 cites W2095675477 @default.
- W2916967884 cites W2098999691 @default.
- W2916967884 cites W2101725657 @default.
- W2916967884 cites W2106116393 @default.
- W2916967884 cites W2107495112 @default.
- W2916967884 cites W2109659042 @default.
- W2916967884 cites W2114876320 @default.
- W2916967884 cites W2116386978 @default.
- W2916967884 cites W2121545342 @default.
- W2916967884 cites W2122995608 @default.
- W2916967884 cites W2128542677 @default.
- W2916967884 cites W2128826373 @default.
- W2916967884 cites W2134471382 @default.
- W2916967884 cites W2136474966 @default.
- W2916967884 cites W2139362357 @default.
- W2916967884 cites W2140490890 @default.
- W2916967884 cites W2141528038 @default.
- W2916967884 cites W2144096834 @default.
- W2916967884 cites W2145442626 @default.
- W2916967884 cites W2145817798 @default.
- W2916967884 cites W2156078931 @default.
- W2916967884 cites W2156373035 @default.
- W2916967884 cites W2160304102 @default.
- W2916967884 cites W2163188200 @default.